A citation-based method for searching scientific literature


List of co-cited articles
399 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
Mihai Gheorghiade, Wendy A Gattis, Christopher M O'Connor, Kirkwood F Adams, Uri Elkayam, Alejandro Barbagelata, Jalal K Ghali, Raymond L Benza, Frank A McGrew, Marc Klapholz,[...]. JAMA 2004
515
20

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
Marvin A Konstam, Mihai Gheorghiade, John C Burnett, Liliana Grinfeld, Aldo P Maggioni, Karl Swedberg, James E Udelson, Faiez Zannad, Thomas Cook, John Ouyang,[...]. JAMA 2007
20

Increased plasma arginine vasopressin levels in patients with congestive heart failure.
S R Goldsmith, G S Francis, A W Cowley, T B Levine, J N Cohn. J Am Coll Cardiol 1983
431
17

Vasopressin: a new target for the treatment of heart failure.
Craig R Lee, Michael L Watkins, J Herbert Patterson, Wendy Gattis, Christopher M O'connor, Mihai Gheorghiade, Kirkwood F Adams. Am Heart J 2003
155
16

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Mihai Gheorghiade, Imran Niazi, John Ouyang, Frank Czerwiec, Jun-ichi Kambayashi, Manuela Zampino, Cesare Orlandi. Circulation 2003
342
16

Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure.
V L Szatalowicz, P E Arnold, C Chaimovitz, D Bichet, T Berl, R W Schrier. N Engl J Med 1981
367
14

Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor.
Y Nakamura, T Haneda, J Osaki, S Miyata, K Kikuchi. Eur J Pharmacol 2000
81
14

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.
J E Udelson, W B Smith, G H Hendrix, C A Painchaud, M Ghazzi, I Thomas, J K Ghali, P Selaru, F Chanoine, M L Pressler,[...]. Circulation 2001
269
14

Hormones and hemodynamics in heart failure.
R W Schrier, W T Abraham. N Engl J Med 1999
825
13

Vasopressin antagonism in heart failure.
Steven R Goldsmith, Mihai Gheorghiade. J Am Coll Cardiol 2005
169
11

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
Mihai Gheorghiade, Marvin A Konstam, John C Burnett, Liliana Grinfeld, Aldo P Maggioni, Karl Swedberg, James E Udelson, Faiez Zannad, Thomas Cook, John Ouyang,[...]. JAMA 2007
616
11

Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.
James E Udelson, Frank A McGrew, Enrique Flores, Hassan Ibrahim, Stewart Katz, Gregory Koshkarian, Terrence O'Brien, Marvin W Kronenberg, Christopher Zimmer, Cesare Orlandi,[...]. J Am Coll Cardiol 2007
125
11

Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study.
Liviu Klein, Christopher M O'Connor, Jeffrey D Leimberger, Wendy Gattis-Stough, Ileana L Piña, G Michael Felker, Kirkwood F Adams, Robert M Califf, Mihai Gheorghiade. Circulation 2005
361
11

Vasopressin V2 receptor antagonists.
L L Wong, J G Verbalis. Cardiovasc Res 2001
60
11


Natriuretic peptides.
E R Levin, D G Gardner, W K Samson. N Engl J Med 1998
10

Upregulation of aquaporin-2 water channel expression in chronic heart failure rat.
D L Xu, P Y Martin, M Ohara, J St John, T Pattison, X Meng, K Morris, J K Kim, R W Schrier. J Clin Invest 1997
231
10

Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial.
Mihai Gheorghiade, Joseph S Rossi, William Cotts, David D Shin, Anne S Hellkamp, Ileana L Piña, Gregg C Fonarow, Teresa DeMarco, Daniel F Pauly, Joseph Rogers,[...]. Arch Intern Med 2007
252
10

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Robert W Schrier, Peter Gross, Mihai Gheorghiade, Tomas Berl, Joseph G Verbalis, Frank S Czerwiec, Cesare Orlandi. N Engl J Med 2006
783
10


OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
Y Yamamura, S Nakamura, S Itoh, T Hirano, T Onogawa, T Yamashita, Y Yamada, K Tsujimae, M Aoyama, K Kotosai,[...]. J Pharmacol Exp Ther 1998
271
8





Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
David Zeltser, Steven Rosansky, Hannes van Rensburg, Joseph G Verbalis, Neila Smith. Am J Nephrol 2007
142
8

Osmotic and nonosmotic control of vasopressin release.
R W Schrier, T Berl, R J Anderson. Am J Physiol 1979
513
7

Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs.
M Naitoh, H Suzuki, M Murakami, A Matsumoto, K Arakawa, A Ichihara, H Nakamoto, K Oka, Y Yamamura, T Saruta. Am J Physiol 1994
85
7


Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.
J L Rouleau, M Packer, L Moyé, J de Champlain, D Bichet, M Klein, J R Rouleau, B Sussex, J M Arnold, F Sestier. J Am Coll Cardiol 1994
242
7

Atrial natriuretic peptide elevation in congestive heart failure in the human.
J C Burnett, P C Kao, D C Hu, D W Heser, D Heublein, J P Granger, T J Opgenorth, G S Reeder. Science 1986
919
7

Diverse biological actions of atrial natriuretic peptide.
B M Brenner, B J Ballermann, M E Gunning, M L Zeidel. Physiol Rev 1990
888
7


The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists.
M Thibonnier, P Coles, A Thibonnier, M Shoham. Annu Rev Pharmacol Toxicol 2001
114
7

Vasopressin receptor antagonists in heart failure.
Marc Thibonnier. Curr Opin Pharmacol 2003
33
15

Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry.
Mihai Gheorghiade, William T Abraham, Nancy M Albert, Wendy Gattis Stough, Barry H Greenberg, Christopher M O'Connor, Lilin She, Clyde W Yancy, James Young, Gregg C Fonarow. Eur Heart J 2007
409
7

The role of vasopressin in congestive heart failure.
Steven R Goldsmith. Cleve Clin J Med 2006
32
15


The Seattle Heart Failure Model: prediction of survival in heart failure.
Wayne C Levy, Dariush Mozaffarian, David T Linker, Santosh C Sutradhar, Stefan D Anker, Anne B Cropp, Inder Anand, Aldo Maggioni, Paul Burton, Mark D Sullivan,[...]. Circulation 2006
7

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure.
T Yatsu, Y Tomura, A Tahara, K Wada, T Kusayama, J Tsukada, T Tokioka, W Uchida, O Inagaki, Y Iizumi,[...]. Eur J Pharmacol 1999
61
6


Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat.
L M Burrell, P A Phillips, J Risvanis, R K Chan, K L Aldred, C I Johnston. Am J Physiol 1998
37
10

Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure.
P Nicod, B Waeber, J P Bussien, J J Goy, G Turini, J Nussberger, K G Hofbauer, H R Brunner. Am J Cardiol 1985
89
5

Natriuretic peptides: a new lipolytic pathway in human adipocytes.
C Sengenès, M Berlan, I De Glisezinski, M Lafontan, J Galitzky. FASEB J 2000
336
5

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
Salim Yusuf, Bertram Pitt, Clarence E Davis, William B Hood, Jay N Cohn. N Engl J Med 1991
5



Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue, T Tanaka. J Pharmacol Exp Ther 1995
74
5

Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane.
S Nielsen, C L Chou, D Marples, E I Christensen, B K Kishore, M A Knepper. Proc Natl Acad Sci U S A 1995
808
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.